Laparoscopic resection of a kidney graft with a tumor, our experience


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. kidney transplantation is currently the "gold standard” for the treatment of patients with end-stage renal disease (ESRD). kidney transplant patients have two-fold increased risk of developing neoplasms compared to the general population. despite the low incidence of transplanted kidney cancer (0.5%), patients in this group require a non-standard approach from clinicians and represent difficult clinical cases. in particular, complications of the treatment of such patients, except for ordinary ones, include an increased likelihood of purulent-septic complications against the background of constant immunosuppressive therapy. material and methods. we performed laparoscopic resection of a transplanted kidney in 12 patients in our clinic in over 3 years. these formations were detected during screening ultrasound of the kidney graft and in ll cases were asymptomatic, only in l case with a 10x9x8.5 cm tumor, the disease manifested as graft dysfunction and an increase in creatinine levels. results. all patients underwent laparoscopic resection of the transplanted kidney. no bleedings or deaths were registered. Conclusion. thus, laparoscopic resection of a transplanted kidney is an effective method for treating such a rare disease as a transplanted kidney cancer; it allows to reduce the mean bed-day, minimize purulent complications, taking into account minimally invasive technologies. it is also worth noting the encouraging oncological prognosis of these patients; the latter statement requires further follow-up of the operated patients.

Full Text

Restricted Access

About the authors

Ruslan N. Trushkin

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: uro52@mail.ru
Dr.Sci. (Med.), Department of Urology 3 Pekhotnaya st., Moscow, 123182

Lyudmila Yu. Artyukhina

City Clinical Hospital № 52 of the Moscow Healthcare Department

Cand.Sci. (Med.), Department of Urology 3 Pekhotnaya st., Moscow, 123182

Damir F. Kantimerov

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: kantimeroff@gmail.com
Cand.Sci. (Med.), Department of Urology 3 Pekhotnaya st., Moscow, 123182

Teimur K. Isaev

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: dr.isaev@mail.ru
Cand.Sci. (Med.), Department of Urology 3 Pekhotnaya st., Moscow, 123182

Nikolay E. Shcheglov

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: nickshch@mail.ru
Department of Urology 3 Pekhotnaya st., Moscow, 123182

Oleg S. Shevtsov

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: shevcovos@yandex.ru
Department of Urology 3 Pekhotnaya st., Moscow, 123182

Tamara M. Klementieva

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: tamara-klementeva@mail.ru
Cand.Sci. (Med.), Department of Urology 3 Pekhotnaya st., Moscow, 123182

References

  1. Wolfe R.A., et al.Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 1999;341(23):1725-30.
  2. Engels E.A., et al. Spectrum of cancer risk among US solid organ transplant recipients. Jama. 2011;306(17):1891-901.
  3. Tillou X., et al. Nephron sparing surgery for De Novo kidney graft tumor: results from a multicenter national study. Am. J. Transplant. 2014;14(9):2120-25.
  4. Nepple K.G., et al. Population based analysis of the increasing incidence of kidney cancer in the United States: evaluation of age specific trends from 1975 to 2006. J. Urol. 2012;187(1):32-8.
  5. Griffith J.J., et al. Solid Renal Masses in Transplanted Allograft Kidneys: A Closer Look at the Epidemiology and Management. Am. J. Transplant. 2017;17(11):2775-81.
  6. Tillou X., et al. Renal cell carcinoma in functional renal graft: Toward ablative treatments. Transplant. Rev. (Orlando). 2016;30(1):20-6.
  7. Su M.Z., Campbell N.A., Lau H.M. Management of renal masses in transplant allografts at an Australian kidney-pancreas transplant unit. Transplant. 2014;97(6):654-59.
  8. Silvestri T., et al. Percutaneous cryoablation of a renal cell carcinoma in a transplanted kidney. Can. J. Urol. 2014;21(4): 7390-92.
  9. Shingleton W.B., Sewell P.E. Percutaneous cryoablation of renal cell carcinoma in a transplanted kidney. BJU.Int. 2002;90(1):137-38.
  10. Végső G., et al. Detection and management of renal cell carcinoma in the renal allograft.Int. Urol. Nephrol. 2013;45(1):93-8.
  11. Krisl J.C., Doan V.P. Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients. Am. J. Transplant. 2017;17(8):1974-91.
  12. Engels E.A., et al. Circulating TGF-β1 and VEGF and risk of cancer among liver transplant recipients. Cancer Med. 2015;4(8):1252-57.
  13. Maluccio M., et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplant. 2003;76(3):597-602.
  14. Dantal J., et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351(9103):623-28.
  15. Schena F.P., et al., Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplant. 2009;87(2):233-42.
  16. Lentini P., et al. Regular ultrasound examination of transplanted kidneys allows early diagnosis of renal cell carcinoma and conservative nephron sparing surgery. Arch. Ital. Urol. Androl. 2011;83(4):195-99.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies